← Back to Clinical Trials
Recruiting NCT05246813
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
Trial Parameters
Condition Osteoporosis
Sponsor Imelda Hospital, Bonheiden
Study Type OBSERVATIONAL
Phase N/A
Enrollment 24
Sex ALL
Min Age 55 Years
Max Age N/A
Start Date 2022-02-11
Completion 2028-12-31
All Conditions
Interventions
Blood and bone marrow cell collection
Brief Summary
Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.
Eligibility Criteria
Inclusion Criteria: * Age 65 years and older Exclusion Criteria: * known haematological condition (myelodysplasia, leukemia, cancer) * inability to provide written informed consent
Related Trials
NCT07141043
Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
View Trial →
NCT06867952
A Pilot Study of Vitamin K2 (Menaquinone-7, Soloways ™) in Patients With Osteopenia/Osteoporosis Car
View Trial →
NCT05246813
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
View Trial →